Veterans Affairs Canada highlighted a recruitment notice for a 30-person clinical pilot studying ketamine and mindfulness therapy for chronic pain and PTSD.
If you are in immediate danger, call 911. For the Veterans Crisis Line, call 988 and press 1, or text 838255. In September 2026, Veterans Affairs Canada published a recruitment notice for a Queen’s University study. The trial is actively recruiting veterans aged 18 to 65 who live with chronic pain, PTSD, or both.
This project is taking place at Providence Care Hospital in Kingston, Ontario. According to a publicly listed trial description, the project is an open-label, randomized, parallel-group pilot trial. The research targets an enrollment of 30 adults with comorbid chronic pain and PTSD.
This recruitment notice highlights a growing institutional interest in integrated healthcare. The Queen’s University project reflects a broader research direction where pain and mental health symptoms are studied together rather than separately. This approach acknowledges that complex conditions often overlap in military populations. The study design directly tests whether adding ketamine to mindfulness-based cognitive therapy is feasible and tolerable compared with mindfulness therapy alone.
It is important to understand the specific limits of this institutional announcement. The Veterans Affairs Canada notice is best understood as a recruitment and research update. It is not evidence that ketamine-assisted psychotherapy has been proven effective for veterans with chronic pain or PTSD. The trial is explicitly intended to generate information for a future, larger study.
A planned sample of 30 participants is appropriate for a pilot trial, but it is too small to establish broad effectiveness across Canada’s veteran population. The veteran-focused evidence base for this type of integrated care remains incomplete. A 2026 Military Medicine case report examined a similar concept at Walter Reed National Military Medical Center. That publication detailed an active-duty service member with neuropathic pain, phantom-limb pain, and complex regional pain syndrome after a transtibial amputation.
The case report authors characterized the approach as feasible and potentially relevant to functional capacity and operational readiness. However, they explicitly labeled their publication a single case report rather than a controlled clinical trial.
While new trials generate interest, established care protocols remain the foundation of veteran health. A separate systematic review examined psychotherapy and medication studies in military personnel. Published in the Journal of Military and Veterans’ Health, the review analyzed trauma-focused psychotherapy and medication for PTSD. The authors reported no statistically significant difference in clinical efficacy between the two approaches in the reviewed veteran populations.
These findings provide a clear rationale for studying new models of integrated care. However, they do not establish that ketamine adds benefit beyond psychotherapy or mindfulness therapy alone. Conventional evidence-based psychotherapy remains an important standard. It should not be displaced while experimental treatments are still being evaluated for feasibility.
Maintaining a clear view of credible military health research helps veterans make informed decisions.
The publicly listed protocol details the exact interventions being tested. The comparison is ketamine-assisted psychotherapy plus mindfulness-based cognitive therapy versus mindfulness-based cognitive therapy alone. For participants assigned to the ketamine treatment group, the protocol consists of four intravenous infusions. These infusions are set at 0.5 mg/kg and administered twice weekly over a two-week period.
The clinical protocol integrates strict mental health components alongside the medical intervention. The study includes eight weekly online mindfulness-based cognitive therapy sessions depending on the participant's assignment. Participants in the ketamine group are also expected to complete five mandatory virtual follow-up visits. Researchers will use questionnaires to track the results across the duration of the pilot trial.
The study’s primary objectives focus strictly on feasibility and ketamine tolerability. Secondary outcomes are designed to capture a wider picture of the participant experience. These secondary metrics track quality of life, pain severity, and physical disability. Researchers will also monitor depressive symptoms, PTSD symptoms, and safety signals.
Veterans Affairs Canada notes that gift cards will be provided to help offset travel and parking costs associated with in-person visits. The trial is described as open-label, meaning participants and study personnel may know which intervention is being delivered. This creates a potential source of expectancy or reporting bias. Recent academic publications offer context for these clinical choices.
Researchers publishing in Military Medicine described ketamine as having demonstrated efficacy in chronic-pain management. They suggested that combining ketamine with psychotherapy may help alleviate psychiatric symptoms. However, they also noted that published research had not examined ketamine infusion integrated with autogenic training for chronic pain prior to their case report.
The Military Medicine report described a 24-hour inpatient ketamine infusion paired with structured autogenic techniques. The participant completed two outpatient preparation sessions before treatment. The authors reported reductions in pain intensity and pain interference immediately after the infusion. These pain reductions continued at one week and one month, while depressive symptoms improved only transiently.
The participant reportedly remained cognitively engaged during the infusion and completed the autogenic protocol.
Veterans considering participation should treat the project strictly as research rather than as an established treatment. Anyone interested should verify whether they qualify under the current protocol. The public recruitment notice and the more detailed trial listing describe the eligible population slightly differently. The detailed listing includes specific exclusions involving recent ketamine or PTSD psychotherapy, substance-use history, and high suicide risk at baseline.
The medical requirements extend beyond basic eligibility. Exclusions also apply to certain psychiatric and medical conditions, medication use, pregnancy or breastfeeding, and the inability to arrange post-infusion supervision. The treatment involves rigorous screening and post-infusion monitoring. The study requires an in-person medical assessment to determine whether participation is safe.
The trial description clearly states that participants must be able to remain for two hours of monitoring after an infusion. Furthermore, participants must arrange for a responsible adult to accompany them home. These requirements highlight the serious medical nature of the intervention. Veterans should maintain their current care plans while considering experimental options.
It is crucial to continue discussing established pain and PTSD treatments with qualified clinicians. Patients should never stop medication or psychotherapy simply because a trial is available. Reviewing veteran lifestyle and healthcare choices requires careful consultation with medical professionals.
For active-duty personnel, the Walter Reed case report provides some insight into physical capability. The report noted no adverse effects in that individual case. However, the evidence is far too limited to support claims that ketamine improves readiness or duty performance. The Walter Reed case required follow-up assessments immediately after treatment.
Medical staff conducted further assessments at one week, one month, and two months. This schedule illustrates the importance of examining whether any early symptom changes persist over time. Finding clear information about veteran life decisions means separating early feasibility studies from proven therapies.
The most useful near-term takeaway is that integrated pain and PTSD care is being actively studied. Effectiveness, durability, safety, and applicability to the wider veteran population remain open questions for research. As medical institutions continue to test these combined therapies, what will future large-scale trials reveal about the long-term safety of ketamine-assisted protocols for veterans?
Follow BattleVet for practical guidance on military and veteran health, strength, recovery, testosterone, sleep and healthy aging. Stay connected for new articles, research backed insights and clear information to help you stay capable for the years ahead.
Gyms are marking the 25th anniversary of 9/11 with 110-flight memorial stair climbs. Learn how to use this event as an annual physical conditioning benchmark.
A September 2026 clinical trial shows a scheduled 30-minute nap opportunity improved simulated crisis performance and leadership skills after a 24-hour shift.
The Pentagon recently withdrew mandatory testosterone screening guidance. Learn how these shifting military medical and privacy policies impact active personnel.
Build better habits around strength, recovery, sleep, hormones and healthy aging with practical guidance for active military personnel and veterans.
Explore BattleVet